OBJECTIVE: To better risk stratify patients, using baseline characteristics, to help optimise decision-making for men with moderate-to-severe lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) through a secondary analysis of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. PATIENTS AND METHODS: After review of the literature, we identified potential baseline risk factors for BPH progression. Using bivariate tests in a secondary analysis of MTOPS data, we determined which variables retained prognostic significance. We then used these factors in Cox proportional hazard modelling to: i) more comprehensively risk stratify the study population based on pre-treatment parameters and ii) to determine which risk strata stood to benefit most from medical intervention. RESULTS: In all, 3047 men were followed in MTOPS for a mean of 4.5 years. We found varying risks of progression across quartiles. Baseline BPH Impact Index score, post-void residual urine volume, serum prostate-specific antigen (PSA) level, age, American Urological Association Symptom Index score, and maximum urinary flow rate were found to significantly correlate with overall BPH progression in multivariable analysis. CONCLUSIONS: Using baseline factors permits estimation of individual patient risk for clinical progression and the benefits of medical therapy. A novel clinical decision tool based on these analyses will allow clinicians to weigh patient-specific benefits against possible risks of adverse effects for a given patient.
OBJECTIVE: To better risk stratify patients, using baseline characteristics, to help optimise decision-making for men with moderate-to-severe lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) through a secondary analysis of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. PATIENTS AND METHODS: After review of the literature, we identified potential baseline risk factors for BPH progression. Using bivariate tests in a secondary analysis of MTOPS data, we determined which variables retained prognostic significance. We then used these factors in Cox proportional hazard modelling to: i) more comprehensively risk stratify the study population based on pre-treatment parameters and ii) to determine which risk strata stood to benefit most from medical intervention. RESULTS: In all, 3047 men were followed in MTOPS for a mean of 4.5 years. We found varying risks of progression across quartiles. Baseline BPH Impact Index score, post-void residual urine volume, serum prostate-specific antigen (PSA) level, age, American Urological Association Symptom Index score, and maximum urinary flow rate were found to significantly correlate with overall BPH progression in multivariable analysis. CONCLUSIONS: Using baseline factors permits estimation of individual patient risk for clinical progression and the benefits of medical therapy. A novel clinical decision tool based on these analyses will allow clinicians to weigh patient-specific benefits against possible risks of adverse effects for a given patient.
Authors: C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher Journal: Urology Date: 1999-03 Impact factor: 2.649
Authors: Nancy N Maserejian; Shan Chen; Gretchen R Chiu; Andre B Araujo; Varant Kupelian; Susan A Hall; John B McKinlay Journal: J Urol Date: 2013-07-10 Impact factor: 7.450
Authors: Steven A Kaplan; John D McConnell; Claus G Roehrborn; Alan G Meehan; Michael W Lee; William R Noble; John W Kusek; Leroy M Nyberg Journal: J Urol Date: 2006-01 Impact factor: 7.450
Authors: Esther Tanja Kok; Boris W Schouten; Arthur M Bohnen; Frans P M W Groeneveld; Siep Thomas; J L H Ruud Bosch Journal: J Urol Date: 2008-12-16 Impact factor: 7.450
Authors: E David Crawford; Shandra S Wilson; John D McConnell; Kevin M Slawin; Michael C Lieber; Joseph A Smith; Alan G Meehan; Oliver M Bautista; William R Noble; John W Kusek; Leroy M Nyberg; Claus G Roehrborn Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Johannes A N Dorresteijn; Frank L J Visseren; Paul M Ridker; Annemarie M J Wassink; Nina P Paynter; Ewout W Steyerberg; Yolanda van der Graaf; Nancy R Cook Journal: BMJ Date: 2011-10-03
Authors: David M Kent; Jason Nelson; Issa J Dahabreh; Peter M Rothwell; Douglas G Altman; Rodney A Hayward Journal: Int J Epidemiol Date: 2016-12-01 Impact factor: 7.196
Authors: Juan Va Franco; Luis Garegnani; Camila Micaela Escobar Liquitay; Michael Borofsky; Philipp Dahm Journal: Cochrane Database Syst Rev Date: 2021-06-28
Authors: Eu Chang Hwang; Shreyas Gandhi; Jae Hung Jung; Mari Imamura; Myung Ha Kim; Ran Pang; Philipp Dahm Journal: Cochrane Database Syst Rev Date: 2018-10-11